Xi'an Xinghui Material Technology Co., Ltd. is not just a workplace, but a 'home' where we grow together and achieve together. We firmly believe that every employee is the company's most valuable asset and the core force driving us forward. Here, we are committed to creating a professional, open, warm, and dynamic environment, allowing every family member to realize their value at work and feel cared for in life.

The EU's Key Medicines Act has entered the implementation phase, requiring the establishment of minimum inventories for key medicines and an increase in the local production ratio of active pharmaceutical ingredients (APIs). The United States continues to support domestic biomanufacturing through tools such as the Defense Production Act.

In vivo gene editing therapies from companies like Intellia/Regeneron and Verve Therapeutics (targeting conditions such as ATTR amyloidosis and hypercholesterolemia) have released longer-term positive data, validating the safety and efficacy of the technology and offering hope for "one-time cures" for common diseases. Related therapies from domestic companies like Boya Jiyin have also entered Phase II clinical trials.